Indaptus Therapeutics is trading 5.31% higher at $2.38, with no clear catalyst identified for the October 8 move.
- The available news check found no fresh company-specific announcement; reported coverage noted the premarket rise without identifying a catalyst.
- Major U.S. indices were lower, but available evidence does not show the gain tracking broad-market sentiment. No volume figure was provided in the supplied price context.